通过向Smad3信号传导来治疗2型糖尿病和糖尿病病
Huijun He1,2, Honglian Wang2, Xiaocui Chen2
1Division of Nephrology, Department of Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, China.
用SIS3针对Smad3显示出治疗2型糖尿病病 (T2DN) 的前景. 在前糖尿病小鼠的早期干预改善了2型糖尿病 (T2D) 和T2DN,而晚期干预只改善了T2DN.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
背景情况:
- 转化生长因子-β (TGF-β) /Smad3信号在2型糖尿病 (T2D) 和2型糖尿病病 (T2DN) 中至关重要.
- 针对Smad3进行T2D和T2DN治疗是一个尚未探索的领域.
研究的目的:
- 研究Smad3抑制剂SIS3对T2D和T2DN的治疗潜力.
- 阐明T2D和T2DN中Smad3抑制的基础机制.
主要方法:
- db/db小鼠在糖尿病前或已确定的糖尿病阶段用SIS3治疗.
- 评估了T2D和T2DN的治疗效果,包括血糖,功能标志物,纤维化和炎症.
- 分析了涉及TGF-β/Smad信号传导,lncRNA和小岛细胞保护的分子机制.
主要成果:
- 糖尿病前的SIS3治疗减轻了T2D和T2DN,降低了血糖,血清肌素,小白蛋白尿,纤维化和炎症.
- 已建立的糖尿病SIS3治疗抑制了T2DN,但没有显著改善T2D.
- 机制包括恢复TGF-β/Smad信号平衡 (抑制Smad3,增加Smad7),通过lncRNA Erbb4-IR和LRN9884.4抑制纤维化和炎症.
- 通过保护Pax 6,改善T2D表型,糖尿病前治疗保护了小岛β细胞.
结论:
- 抑制Smad3是T2DN的潜在治疗策略.
- 使用Smad3抑制剂的早期干预可以通过保护小岛功能来为T2D和T2DN提供好处.
- 这些发现突出了T2DN病原体和潜在的治疗点中涉及的特定分子通路.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
TGF - β Signaling Pathway
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
